Trial Profile
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary) ; Insulin degludec; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PRONTO-T2D
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan
- 01 Jan 2024 Results of pooled analysis from PRONTO-T1D and PRONTO-T2D , investigating contributions of changes in fasting plasma glucose (FPG) and postprandial glucose (PPG) to changes in hemoglobin A1c (HbA1c) and time-in-range (TIR, 70-180 mg/dL) in people with type 1 diabetes , published in the Journal of Diabetes and its Complications
- 04 Jul 2022 Results of subgroup analysis assessing efficacy and safety of URLi compared to lispro in younger versus older patients in PRONTO-T2D published in the Diabetes Therapy
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes